tiprankstipranks
Advertisement
Advertisement

ESALF Stock Latest News

Eisai Earnings Call Highlights LEQEMBI-Led Growth
Company AnnouncementsEisai Earnings Call Highlights LEQEMBI-Led Growth
5d ago
Eisai’s E2086 Narcolepsy Trial Adds Quiet Upside Optionality for ESALF Investors
PremiumCompany Announcements
Eisai’s E2086 Narcolepsy Trial Adds Quiet Upside Optionality for ESALF Investors
10d ago
ESALF
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
11d ago
Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
PremiumCompany Announcements
Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
26d ago
ESALF
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
PremiumCompany Announcements
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
1M ago
ESALF
Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
PremiumCompany AnnouncementsEisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
3M ago
ESALF
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
Premium
Company Announcements
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
3M ago
ESALF
ESALF Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ESALF Earnings this Week: How Will it Perform?
4M ago
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
PremiumCompany Announcements
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
7M ago
ESALF
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
PremiumCompany Announcements
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
7M ago
ESALF
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
7M ago
ESALF
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
PremiumCompany Announcements
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
7M ago
ESALF
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
PremiumCompany AnnouncementsEisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
7M ago
ESALF
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
Premium
Company Announcements
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
7M ago
ESALF
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
Premium
Company Announcements
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
7M ago
ESALF
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
PremiumCompany Announcements
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
7M ago
ESALF
Eisai’s Tazemetostat Study: A Key Update for Investors
PremiumCompany Announcements
Eisai’s Tazemetostat Study: A Key Update for Investors
7M ago
ESALF
Is ESALF a Buy, Before Earnings?
PremiumPre-Earnings
Is ESALF a Buy, Before Earnings?
10M ago
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
10M ago
ESALF
Eisai Co. Advances Cancer Treatment with E7389 Liposomal Study
PremiumCompany AnnouncementsEisai Co. Advances Cancer Treatment with E7389 Liposomal Study
10M ago
ESALF
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
Premium
Company Announcements
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
11M ago
ESALF
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
Premium
Company Announcements
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
11M ago
ESALF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >